GlaxoSmithKline Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . GlaxoSmithKline PLC ADR
GSK Stock  USD 39.85  0.33  0.84%   
Analyzing historical trends in various income statement and balance sheet accounts from GlaxoSmithKline PLC's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting GlaxoSmithKline PLC's valuation are summarized below:
Gross Profit
22.7 B
Profit Margin
0.1082
Market Capitalization
80.2 B
Enterprise Value Revenue
2.3252
Revenue
31.6 B
There are currently one hundred twenty fundamental trends for GlaxoSmithKline PLC ADR that can be evaluated and compared over time across competitors. We recommend to confirm GlaxoSmithKline PLC's regular fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 40.8 B. The Enterprise Value is projected to slide to about 44.2 B

GlaxoSmithKline PLC Total Revenue

20.29 Billion

Check GlaxoSmithKline PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GlaxoSmithKline PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.7 B, Interest Expense of 507.3 M or Total Revenue of 20.3 B, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0394 or PTB Ratio of 3.81. GlaxoSmithKline financial statements analysis is a perfect complement when working with GlaxoSmithKline PLC Valuation or Volatility modules.
  
Build AI portfolio with GlaxoSmithKline Stock
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.

GlaxoSmithKline PLC Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.6 B59.5 B52.8 B
Slightly volatile
Short and Long Term Debt Total11.2 B17 B18.6 B
Slightly volatile
Other Current Liabilities15.9 B15.2 B9.4 B
Slightly volatile
Total Current Liabilities11.5 B21.7 B17.8 B
Slightly volatile
Property Plant And Equipment Net7.2 B10.1 B9.3 B
Slightly volatile
Net Debt8.4 B13.3 B14.5 B
Slightly volatile
Accounts Payable3.2 B3.5 B5.6 B
Very volatile
Cash2.8 B3.7 B4.2 B
Very volatile
Non Current Assets Total21.5 B42.5 B37 B
Slightly volatile
Cash And Short Term Investments3.9 B3.7 B4.7 B
Pretty Stable
Net Receivables4.1 B6 B5.4 B
Slightly volatile
Common Stock Shares Outstanding1.7 B2.1 B1.9 B
Pretty Stable
Short Term Investments19.9 M21 M496.4 M
Slightly volatile
Liabilities And Stockholders Equity33.6 B59.5 B52.8 B
Slightly volatile
Non Current Liabilities Total14.6 B24.7 B25.4 B
Slightly volatile
Inventory3.1 B5.7 B4.6 B
Slightly volatile
Other Current Assets2.1 B1.6 B2.6 B
Very volatile
Other Stockholder Equity4.8 B4.5 B3.6 B
Slightly volatile
Total Liabilities26.1 B46.4 B43.2 B
Slightly volatile
Property Plant And Equipment Gross21.6 B20.6 B11.4 B
Slightly volatile
Total Current Assets12.1 B17 B15.9 B
Slightly volatile
Capital Stock1.3 B1.6 B1.3 B
Slightly volatile
Short Term Debt2.2 B2.3 B3.2 B
Pretty Stable
Common Stock1.3 B1.6 B1.3 B
Slightly volatile
Intangible Assets9.5 B15.5 B15.7 B
Slightly volatile
Other Liabilities14.2 B11.7 B17.3 B
Very volatile
Long Term Debt17.4 B13.7 B18.1 B
Very volatile
Good Will5.4 B7 B6.1 B
Slightly volatile
Property Plant Equipment9.6 B10.1 B11.3 B
Slightly volatile
Other Assets5.6 B7.7 B5.3 B
Slightly volatile
Long Term Investments77.6 B73.9 B35.9 B
Slightly volatile
Short and Long Term Debt4.1 B2.2 B7.5 B
Slightly volatile
Additional Paid In Capital3.4 B4 B3.1 B
Slightly volatile
Long Term Debt Total19.7 B14.6 B17.2 B
Slightly volatile
Capital Surpluse3.5 B3.5 B3.1 B
Slightly volatile
Net Invested Capital21.4 B29.6 B22.1 B
Slightly volatile
Cash And Equivalents2.3 B2.8 B3.5 B
Slightly volatile

GlaxoSmithKline PLC Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.7 B2.6 B1.9 B
Slightly volatile
Interest Expense507.3 M640 M720.1 M
Pretty Stable
Total Revenue20.3 B31.4 B26.9 B
Slightly volatile
Gross Profit14.9 B22.3 B18.3 B
Slightly volatile
Other Operating Expenses15.7 B27.4 B21.9 B
Slightly volatile
Operating Income5 B4 B5.8 B
Very volatile
EBIT4.8 B4.1 B5.7 B
Pretty Stable
Research Development6.7 B6.4 B4.4 B
Slightly volatile
EBITDA6 B6.7 B7.5 B
Slightly volatile
Total Operating Expenses10.3 B18.3 B13.3 B
Slightly volatile
Income Before Tax4.8 B3.5 B5.2 B
Very volatile
Net Income3.4 B2.6 B4 B
Very volatile
Income Tax Expense499.7 M526 M941.4 M
Slightly volatile
Selling General Administrative9.6 B11 B8.8 B
Slightly volatile
Cost Of Revenue7.7 B9 B8.8 B
Slightly volatile
Net Income Applicable To Common Shares2.4 B2.6 B5.6 B
Pretty Stable
Selling And Marketing Expenses317.2 M333.9 M1.1 B
Slightly volatile
Net Income From Continuing Ops2.8 B3 B9.5 B
Pretty Stable
Tax Provision644.5 M526 M1.2 B
Slightly volatile
Interest Income57 M60 M452.9 M
Slightly volatile
Reconciled Depreciation2.4 B2.6 B2.1 B
Slightly volatile

GlaxoSmithKline PLC Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow3.4 B3.6 B4.2 B
Slightly volatile
Begin Period Cash Flow2.2 B2.9 B4.1 B
Pretty Stable
Depreciation1.4 B2.6 B1.8 B
Slightly volatile
Capital Expenditures1.6 B3 B2 B
Slightly volatile
Total Cash From Operating Activities5 B6.6 B6.1 B
Slightly volatile
Net Income4.6 B3 B4.3 B
Pretty Stable
End Period Cash Flow2.1 B3.4 B3.9 B
Pretty Stable
Dividends Paid3.4 B2.4 B3.5 B
Very volatile
Stock Based Compensation338 M344 M317.3 M
Slightly volatile
Change To Liabilities596.5 M568.1 M283.9 M
Slightly volatile
Issuance Of Capital Stock26.3 M20 M53 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.661.74962.6621
Slightly volatile
Dividend Yield0.03940.04450.0595
Very volatile
Days Sales Outstanding86.3480.675578.0484
Pretty Stable
Book Value Per Share3.373.20972.616
Slightly volatile
Free Cash Flow Yield0.04320.06510.0711
Slightly volatile
Operating Cash Flow Per Share0.881.60761.5553
Slightly volatile
Stock Based Compensation To Revenue0.00860.0110.0109
Pretty Stable
Capex To Depreciation1.471.1691.2458
Slightly volatile
EV To Sales2.062.16773.1764
Slightly volatile
Free Cash Flow Per Share0.60.87611.0533
Slightly volatile
ROIC0.230.11930.1517
Slightly volatile
Inventory Turnover2.061.67151.8011
Very volatile
Net Income Per Share0.640.63161.1664
Pretty Stable
Days Of Inventory On Hand160218205
Pretty Stable
Payables Turnover3.962.73712.6116
Slightly volatile
Sales General And Administrative To Revenue0.460.410.3788
Pretty Stable
Research And Ddevelopement To Revenue0.110.17520.137
Slightly volatile
Capex To Revenue0.08230.0950.0812
Very volatile
Cash Per Share0.70.95441.2042
Pretty Stable
POCF Ratio7.968.376112.4441
Slightly volatile
Interest Coverage8.358.791913.9596
Slightly volatile
Payout Ratio0.820.94911.14
Very volatile
Capex To Operating Cash Flow0.480.4550.3902
Pretty Stable
PFCF Ratio14.615.3686268
Slightly volatile
Days Payables Outstanding175133189
Slightly volatile
Income Quality2.332.22091.8382
Pretty Stable
EV To Operating Cash Flow9.8610.377314.843
Slightly volatile
PE Ratio27.8521.319120.2712
Pretty Stable
Return On Tangible Assets0.06620.06970.1455
Pretty Stable
EV To Free Cash Flow18.0919.0405278
Slightly volatile
Earnings Yield0.04790.04690.0806
Pretty Stable
Intangibles To Total Assets0.40.37830.3702
Slightly volatile
Net Debt To EBITDA2.061.96491.9807
Slightly volatile
Current Ratio1.490.78341.0325
Slightly volatile
Receivables Turnover4.34.52434.7518
Pretty Stable
Graham Number3.986.9037.0586
Slightly volatile
Capex Per Share0.770.73140.5325
Slightly volatile
Revenue Per Share8.087.69596.9534
Slightly volatile
Interest Debt Per Share4.544.32435.0804
Slightly volatile
Debt To Assets0.220.28570.3332
Pretty Stable
Enterprise Value Over EBITDA16.1410.189211.2197
Pretty Stable
Short Term Coverage Ratios2.272.79011.9803
Slightly volatile
Price Earnings Ratio27.8521.319120.2712
Pretty Stable
Operating Cycle173299260
Slightly volatile
Days Of Payables Outstanding175133189
Slightly volatile
Dividend Payout Ratio0.820.94911.14
Very volatile
Price To Operating Cash Flows Ratio7.968.376112.4441
Slightly volatile
Price To Free Cash Flows Ratio14.615.3686268
Slightly volatile
Pretax Profit Margin0.110.11080.2042
Slightly volatile
Ebt Per Ebit1.030.61410.8688
Pretty Stable
Operating Profit Margin0.320.18050.2528
Slightly volatile
Effective Tax Rate0.290.15130.2046
Slightly volatile
Long Term Debt To Capitalization0.370.50060.6328
Very volatile
Total Debt To Capitalization0.420.55410.6756
Very volatile
Return On Capital Employed0.140.14990.2039
Slightly volatile
Ebit Per Revenue0.320.18050.2528
Slightly volatile
Quick Ratio0.50.52210.7065
Slightly volatile
Dividend Paid And Capex Coverage Ratio0.841.20791.1254
Pretty Stable
Net Income Per E B T0.60.74060.8641
Slightly volatile
Cash Ratio0.170.17840.2373
Slightly volatile
Cash Conversion Cycle84.3166133
Pretty Stable
Operating Cash Flow Sales Ratio0.160.20890.2229
Pretty Stable
Days Of Inventory Outstanding160218205
Pretty Stable
Days Of Sales Outstanding86.3480.675578.0484
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.450.5450.6055
Pretty Stable
Cash Flow Coverage Ratios0.570.38580.3596
Very volatile
Fixed Asset Turnover2.13.11492.7915
Pretty Stable
Capital Expenditure Coverage Ratio2.662.19793.06
Very volatile
Price Cash Flow Ratio7.968.376112.4441
Slightly volatile
Enterprise Value Multiple16.1410.189211.2197
Pretty Stable
Debt Ratio0.220.28570.3332
Pretty Stable
Cash Flow To Debt Ratio0.570.38580.3596
Very volatile
Price Sales Ratio1.661.74962.6621
Slightly volatile
Return On Assets0.04110.04330.095
Slightly volatile
Asset Turnover0.780.52770.5467
Slightly volatile
Net Profit Margin0.0780.08210.1773
Pretty Stable
Gross Profit Margin0.790.6980.6968
Pretty Stable

GlaxoSmithKline PLC Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap40.8 B46.8 B49.1 B
Pretty Stable
Enterprise Value44.2 B61.1 B62.8 B
Pretty Stable

GlaxoSmithKline Fundamental Market Drivers

Forward Price Earnings7.6923
Cash And Short Term Investments3.7 B

GlaxoSmithKline Upcoming Events

31st of January 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About GlaxoSmithKline PLC Financial Statements

GlaxoSmithKline PLC investors utilize fundamental indicators, such as revenue or net income, to predict how GlaxoSmithKline Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue255.3 M268.1 M
Total Revenue31.4 B20.3 B
Cost Of Revenue9 B7.7 B
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.41  0.46 
Research And Ddevelopement To Revenue 0.18  0.11 
Capex To Revenue 0.10  0.08 
Revenue Per Share 7.70  8.08 
Ebit Per Revenue 0.18  0.32 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
How To Invest In GlaxoSmithKline
Details
Is GlaxoSmithKline Stock a good investment?
Details
What is GlaxoSmithKline PLC's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of GlaxoSmithKline PLC Correlation against competitors.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.232
Dividend Share
0.63
Earnings Share
2.22
Revenue Per Share
15.512
Quarterly Revenue Growth
0.013
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY